Search

everythinglearnresearchcommunity

for

Search:↓

Finasteride may help some male chronic pelvic pain patients, but more research needed.

Combining dutasteride or finasteride with an α1 blocker is more effective for managing BPH than using either alone.

A new compound may effectively inhibit the enzyme linked to BPH and hair loss.

Current treatments for recurrent ischemic priapism are not well-defined and need more research.

Dutasteride use can lead to a stable decline in sexual function that is not affected by age or prostate size.

Finasteride may cause sexual dysfunction by reducing epinephrine levels.

The conclusion is that future trials should report specific details about the PRP composition to better understand its effects on urologic conditions.

Epristeride's metabolism in zebrafish helps improve doping detection methods.

A peptide known for reducing wrinkles also effectively inhibits an enzyme linked to skin inflammation and acne.

Dutasteride is approved to help manage prostate enlargement.

Low-intensity shock wave therapy is effective in treating erectile dysfunction in diabetic patients.

5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.

Platelet-rich plasma can improve erectile function in older individuals by reducing prostate enlargement.

The Princeton III Consensus recommends assessing cardiovascular risk in men with erectile dysfunction and prioritizing heart health before treating ED, especially in those with potential heart disease.

Combining α1-blockers with 5α-reductase inhibitors improves urinary symptoms in men.

Nifedipine may help treat perniosis, improving symptoms and clearing lesions for some patients.

Finasteride may be linked to Peyronie’s disease, but more research is needed.

Certain derivatives are more effective 5α-reductase type 2 inhibitors than finasteride.

New treatments for enlarged prostate are being developed, some of which may be more effective than current medications.

More research is needed to find effective treatments for sickle cell disease-related priapism.

Finasteride helps improve treatment for benign prostatic hyperplasia.

MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.

Medications for BPH can have significant side effects, so understanding these risks is important for treatment decisions.

5α-reductase inhibitors, like Finasteride and Dutasteride, help manage benign prostatic hyperplasia.

Triple Hormonal Blockade (ADT3) can effectively manage prostate cancer but requires careful monitoring for heart risks.

Dutasteride potentially improves cell survival and reduces retinal damage in retinitis pigmentosa.

5-alpha-reductase inhibitors can effectively treat benign prostatic hyperplasia.